To the best of our knowledge, this study is the first to demonstrate this superior efficacy of premixed insulin over basal insulin treatment in attaining the target HbA1c for Chinses T2DM outpatients with insulin monotherapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.